08:37 AM EDT, 09/26/2024 (MT Newswires) -- AbbVie ( ABBV ) said Thursday topline results from a phase 3 trial of tavapadon as a monotherapy in early Parkinson's disease met its primary endpoint, as well as a key secondary endpoint.

The company said patients treated with tavapadon in both dose groups experienced a 'statistically significant reduction (improvement)' from baseline compared to placebo. It said the results also showed a 'statistically significant and clinically meaningful improvement' in motor aspects of experiences of daily living in both tavapadon dose groups compared to placebo at week 26.

AbbVie ( ABBV ) said it expects topline results from the phase 3 flexible-dose monotherapy trial for tavapadon to be announced by the end of the year.

Price: 190.99, Change: -0.27, Percent Change: -0.14